STOCK TITAN
  1. Home
  2. Sec-filings
  3. HALO
  4. [ARS] HALOZYME THERAPEUTICS, INC. SEC Filing

[ARS] HALOZYME THERAPEUTICS, INC. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
ARS
ARS - HALOZYME THERAPEUTICS, INC.

ARS Filing - HALOZYME THERAPEUTICS, INC.

This filing is available as a PDF document.

Filing Type: ARS

Company: HALOZYME THERAPEUTICS, INC. (HALO)

Acceptance Date: 2026-03-23T16:16:26.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Halozyme Thrp

NASDAQ:HALO

View HALO Stock Overview →

HALO Rankings

#1092 Ranked by Market Cap
N/A Ranked by Dividends

HALO Latest News

Mar 12, 2026
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
Mar 6, 2026
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
Feb 25, 2026
Halozyme to Participate in Upcoming Investor Conferences
Feb 17, 2026
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
Jan 28, 2026
/C O R R E C T I O N -- Nootropics Depot/

HALO Latest SEC Filings

Mar 23, 2026
[Form 3] HALOZYME THERAPEUTICS, INC. Initial Statement of Beneficial Ownership
Mar 23, 2026
[DEF 14A] HALOZYME THERAPEUTICS, INC. Definitive Proxy Statement
Mar 12, 2026
[8-K] HALOZYME THERAPEUTICS, INC. Reports Material Event
Mar 10, 2026
[Form 4] HALOZYME THERAPEUTICS, INC. Insider Trading Activity
Mar 10, 2026
[144] HALOZYME THERAPEUTICS, INC. SEC Filing

HALO Stock Data

7.49B
116.54M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
SAN DIEGO